

Clinical, morphological, biochemical, imaging and outcome parameters in 21 individuals with mitochondrial maintenance defect related to *FBXL4* mutations

Martina Huemer^{1,2,3} · Daniela Karall⁴ · Anna Schossig⁵ · Jose E. Abdenur^{6,7} · Fatma Al Jasmi⁸ · Caroline Biagosch^{9,10} · Felix Distelmaier¹¹ · Peter Freisinger¹² · Brett H. Graham¹³ · Tobias B. Haack^{9,10} · Natalie Hauser¹⁴ · Jozef Hertecant¹⁵ · Darius Ebrahimi-Fakhari¹⁶ · Vassiliki Konstantopoulou¹⁷ · Karen Leydiker⁶ · Charles M. Lourenco¹⁸ · Sabine Scholl-Bürgi⁴ · Ekkehard Wilichowski¹⁹ · Nicole I. Wolf²⁰ · Saskia B. Wortmann²¹ · Robert W. Taylor²² · Johannes A. Mayr²³ · Penelope E. Bonnen¹³ · Wolfgang Sperl²³ · Holger Prokisch^{9,10} · Robert McFarland²²

Received: 15 January 2015 / Accepted: 9 March 2015 / Published online: 14 April 2015
© SSIEM 2015

Abstract *FBXL4* deficiency is a recently described disorder of mitochondrial maintenance associated with a loss of mitochondrial DNA in cells. To date, the genetic diagnosis of

FBXL4 deficiency has been established in 28 individuals. This paper retrospectively reviews proxy-reported clinical and biochemical findings and evaluates brain imaging, morphological

Communicated by: Eva Morava

Martina Huemer, Daniela Karall, Wolfgang Sperl, Holger Prokisch and Robert McFarland contributed equally to this work.

Electronic supplementary material The online version of this article (doi:10.1007/s10545-015-9836-6) contains supplementary material, which is available to authorized users.

✉ Martina Huemer
martina.huemer@lkhb.at

- ¹ Department of Pediatrics, Landeskrankenhaus Bregenz, Carl-Pedenz-Str. 2, 6900 Bregenz, Austria
- ² Division of Metabolism, University Children's Hospital Zürich, Zürich, Switzerland
- ³ radiz – Rare Disease Initiative Zürich, University Zürich, Zürich, Switzerland
- ⁴ Clinic for Pediatrics I, Inherited Metabolic Disorders, Medical University of Innsbruck, Innsbruck, Austria
- ⁵ Division of Human Genetics, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria
- ⁶ Division of Metabolic Disorders, CHOC Children's, Orange, CA, USA
- ⁷ Department of Pediatrics, University of California at Irvine (UCI), Irvine, CA, USA
- ⁸ Department of Pediatrics, College of Medicine and Health Sciences, United Arab Emirates University, Al Ain, United Arab Emirates

- ⁹ Institute of Human Genetics, Technische Universität München, Munich, Germany
- ¹⁰ Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany
- ¹¹ Department of General Pediatrics, Neonatology and Pediatric Cardiology, University Children's Hospital, Heinrich-Heine-University, Düsseldorf, Germany
- ¹² Klinikum am Steinenberg, Childrens' Hospital, Reutlingen, Germany
- ¹³ Department of Molecular and Human Genetics, Baylor College of Medicine, Houston, Texas, USA
- ¹⁴ Childrens' Hospital Central California, Madera, California, USA
- ¹⁵ Department of Pediatrics, Tawam Hospital, Al Ain, UAE
- ¹⁶ Department of Pediatrics, University Hospital, Heidelberg, Germany
- ¹⁷ Department of Pediatrics, Medical University of Vienna, 1090 Vienna, Austria
- ¹⁸ Neurogenetics Unit. Department of Neurology, University of Sao Paulo, Sao Paulo, Brazil

and genetic data in 21 of those patients. Neonatal/early-onset severe lactic acidosis, muscular hypotonia, feeding problems and failure to thrive is the characteristic pattern at first presentation. Facial dysmorphic features are present in 67 % of cases. Seven children died (mean age 37 months); 11 children were alive (mean age at follow-up 46 months), three children were lost to follow-up. All survivors developed severe psychomotor retardation. Brain imaging was non-specific in neonates but a later-onset, rapidly progressive brain atrophy was noted. Elevated blood lactate and metabolic acidosis were observed in all individuals; creatine kinase was elevated in 45 % of measurements. Diagnostic workup in patient tissues and cells revealed a severe combined respiratory chain defect with a general decrease of enzymes associated with mitochondrial energy metabolism and a relative depletion of mitochondrial DNA content. Mutations were detected throughout the *FBXL4* gene albeit with no clear delineation of a genotype-phenotype correlation. Treatment with “mitochondrial medications” did not prove effective. In conclusion, a clinical pattern of early-onset encephalopathy, persistent lactic acidosis, profound muscular hypotonia and typical facial dysmorphism should prompt initiation of molecular genetic analysis of *FBXL4*. Establishment of the diagnosis permits genetic counselling, prevents patients undergoing unhelpful diagnostic procedures and allows for accurate prognosis.

Introduction

FBXL4 is a protein involved in phosphorylation-directed ubiquitination (Cenciarelli et al 1999; Winston et al 1999) but recently shown to contain a mitochondrial localization signal and found within mitochondria (Bonnen et al 2013; Gai et al 2013). In fibroblasts from patients with biallelic *FBXL4* mutations, a disturbance of the mitochondrial network, decreased activity of enzymes associated with mitochondrial energy metabolism and depletion of mitochondrial DNA (mtDNA) content in relation to nuclear DNA has been shown (Bonnen et al 2013; Gai et al 2013). Thus, although the precise function of *FBXL4* remains undetermined, there is

strong evidence to support an important role in mtDNA maintenance or mitochondrial maintenance *per se* (Bonnen et al 2013; Gai et al 2013). In contrast to other disorders of mtDNA maintenance, *FBXL4* deficiency (MIM 615471) leads to a decrease in mitochondrial mass within the cell although the mechanism of this presumed pathologically-relevant process remains unclear.

To date, *FBXL4* mutations have been mainly identified through whole exome sequencing initiated in children with encephalopathy, muscular hypotonia, persistent lactic acidosis and combined mitochondrial respiratory chain deficiencies in skeletal muscle tissue (Bonnen et al 2013; Gai et al 2013). The aim of the present study was to analyse whether individuals with proven *FBXL4* mutations share clinical, neuroradiological or biochemical features which might facilitate earlier diagnosis. In addition, by collating the extensive clinical information and DNA sequencing data available from 21 patients we have explored the possibility of genotype-phenotype associations.

Methods

Data on patients’ genotype, phenotype, clinical course, biochemical and neuroradiological findings were obtained by means of a questionnaire from physicians involved in the clinical care and follow-up of individuals with *FBXL4* mutations. Contact addresses of the physicians were retrieved from the databases of referrers of diagnostic material to specialized laboratories and from specialist networks. Caregivers gave their consent to submit the retrospective data in pseudonymized form to their physicians.

A “Survey Monkey” questionnaire was constructed (provided as [supplementary material](#)) based on published features encountered in individuals with *FBXL4* mutations and in addition, included open questions addressing yet unpublished symptoms and organ involvement. Furthermore, physicians were asked to send their patient’s brain MRI images to have them assessed by an experienced child neurologist.

The activity of respiratory chain enzymes, pyruvate dehydrogenase and citrate synthase was determined in different diagnostic laboratories according to published standard methods (Berger et al 2003; Meierhofer et al 2004; Kirby et al 2007; Feichtinger et al 2014). The relative content of mtDNA per nuclear genome was determined by quantitative real-time PCR (Acham-Roschitz et al 2009). Immunohistochemical staining was performed with formalin-fixed muscle tissue as reported previously (Feichtinger et al 2010).

All patients were genetically diagnosed by whole exome sequencing (Haack et al 2014) or Sanger sequencing (primer and PCR conditions are available on request). Splice site mutations were predicted by the mutation taster (Schwarz et al

¹⁹ Department of Paediatrics and Adolescent Medicine, Division of Pediatric Neurology, University Medical Center Göttingen, Georg August University, Göttingen, Germany

²⁰ Department of Child Neurology, VU University Medical Center, and Neuroscience Campus Amsterdam, Amsterdam, The Netherlands

²¹ Amalia Children’s Hospital, RadboudUMC Nijmegen, Nijmegen, The Netherlands

²² Wellcome Trust Centre for Mitochondrial Research, Institute of Neuroscience, Newcastle University, Newcastle upon Tyne, UK

²³ Department of Pediatrics, Paracelsus Medical University Salzburg, Salzburg, Austria

2010) and post-translational modification sites by PTMcode. The alignment (ClustalW2; embl-ebi) consists of the following species (with corresponding uniprot identifiers), *Homo sapiens* (Q9UKA2), *Pan troglodytes* (H2QTF8), *Macaca mulatta* (F7G6N0), *Mus musculus* (V9GXH8), *Bos taurus* (F1N1M5), *Gallus gallus* (E1C3J3), *Xenopus tropicalis* (K9J7L5), *Danio rerio* (Q5U388).

Results

Fourteen physicians reported data on 21 affected children (13 males, eight females) from 19 families (two pairs of siblings). Three children (two males, one female) have been published before by Gai et al 2013, one male has been published by Bonnen et al 2013 (see Supplementary Tables 1 and 2). Probably affected, but genetically unconfirmed, siblings were encountered in four additional families. Parental consanguinity was present in 58 % of families. Eight children were of Arabian (two siblings), four of Middle and South European, three of Turkish, two (siblings) of Mexican (Zacatecas/Guanajuato), and one each of Palestinian, Pakistani and Portuguese/African American descent. Ethnic background was unknown for one case.

General paediatricians and specialists in paediatric metabolic medicine or paediatric neurology performed clinical assessment of all patients. The majority of patients were born at term (mean and median gestational week 38; range 35–41; $n=19$). Birth weight was below the 3rd centile in six individuals and normal, but predominantly in the low centile range ($n=10$ between 3rd and 50th, $n=2>50$ th percentile) (Barbier et al 2013) for the others. Data on head circumference at birth were available for only five individuals and below the 3rd centile in two/five children.

Clinical symptoms at initial workup and during the disease course

Age at onset of first symptoms and at follow-up

First symptoms occurred very early in life (mean 115 days, median 2 days, range 1d-24 months) with 14 patients presenting symptoms in the neonatal period while another five patients first exhibited disease between 3 and 12 months of age. A further two patients showed a somewhat later onset at the age of 17 and 24 months, respectively. At the time of the study, 11 children are alive (mean age at follow-up 46 months; median 41 months, range 2–139 months) while seven individuals had died (mean age at death 37 months; median 26 months, range 24–75 months). No information was available for three subjects.

Typical pattern of symptoms at first presentation

Main clinical features for the cohort over time are depicted in Fig. 1. More than 80 % of patients presented with failure to thrive/feeding problems, muscular hypotonia and neurodevelopmental impairment at initial workup combined with elevated lactate and metabolic acidosis.

Typical pattern of symptoms during the disease course

As the disease evolved, neurocognitive impairment, commonly severe psychomotor retardation and developmental delay, became readily apparent, but perhaps surprisingly, there were few individuals with features often associated with central nervous system involvement of mitochondrial disease such as seizures, hearing impairment and movement disorders (Fig. 1).

Cardiac disease

Cardiac disease was noticed at first presentation in seven subjects and evolved in another patient during the course. Non-progressive cardiomyopathy was present in two individuals at presentation. Left ventricular non-compaction, borderline left ventricular hypertrophy and hyperdynamic left ventricular systolic function and small combined atrial and ventricular septum defects were each present in a single child. No detailed information was available for four patients, including the single patient developing cardiac involvement during the course of the disease. Other visceral organs were very rarely affected.

Rarely reported symptoms: eye disease

Congenital cataracts were present in two children and optic nerve atrophy with significant visual impairment evolved during the course of the illness in one female.


Rarely reported symptoms: neutropenia

One child presented with episodic neutropenia associated with recurrent infections. In another child, persistent neutropenia was accompanied by recurrent infections and wound healing deficit. The patient died from fatal gastrointestinal bleeding 1 year after placement of a percutaneous endoscopic gastrostomy (PEG) tube.

Late-onset symptoms

A female patient aged 11 years 7 months at last follow-up and thus representing by far the oldest individual in the cohort (mean 46 months) developed ptosis, sensorineural hearing loss, optic nerve atrophy with significant visual impairment and stroke (at age 10 years) causing left sided spastic

Fig. 1 Main clinical features at initial workup and during the course in 21 patients with *FBXL4* mutations



hemiparesis besides the above mentioned episodic neutropenia. Individual courses are described in Supplementary Table 1.

Physicians' overall assessment of the disease course

The course of the disease was considered by the physicians to improve over time in one case; remain stable in seven and deteriorate in ten individuals ($n=18$). Seven children died at a mean age of 37 months, mostly from multiorgan failure associated with overwhelming metabolic acidosis, which in some cases was triggered by infections. All survivors developed severe psychomotor retardation. Only one child was able to walk with assistance while 14 of 15 were completely unable to do so. Fifteen of 16 children had no or severely impaired functional speech and communicative abilities.

Treatment and physicians' overall assessment of outcome

Treatment approaches included coenzyme Q₁₀ in six, riboflavin in three, long-term sodium bicarbonate in four, sodium citrate in two, carnitine in four, thiamine, biotin, vitamin D and folate in two individuals each. Bezafibrate, high fat diet or low protein diet were applied in a single case each. One female with neutropenia required treatment with granulocyte colony stimulating factor. Fifty-seven percent of 21 patients received more than one medication, 38 % never had specific "mitochondrial" treatment. Physicians' overall assessments underpin the severity of handicap and the limited biochemical and clinical response to treatment. Physicians agreed or strongly agreed to the statement "my patient shows no biochemical response to treatment" in 61 %; to the statement "my patient shows no clinical response to treatment" in 72 % and to the statement "my patient is severely handicapped" in 93 % of cases. In addition, physicians stated that both patients' and parental quality of life was severely impaired (93 % of cases).

Dysmorphic features


Dysmorphic features or malformations were reported in 67 % of the affected individuals (supplementary table 1). Figure 2 illustrates the typical facial appearance of the patients such as prominent forehead; thick, diffuse eyebrows and synophris; short, upslanting palpebral fissures; broad nasal root with depressed nasal bridge; smooth philtrum, and low set, dysplastic ears.

Brain imaging

Data on brain magnetic resonance imaging were available for 14 cases; serial imaging had been performed in six children. Central assessment of the imaging series by an experienced child neurologist was possible for 11 cases. Cerebellar hypoplasia was present in two patients. Five children were imaged during the neonatal period, between 4 and 10 days of age. All had increased white matter signal on the T2-weighted and correspondingly reduced signal on the T1-weighted images. In addition, the white matter appeared swollen, indicating increased water content (Fig. 3a-f). In some children, diffusion-weighted imaging was available with increased diffusivity in the supratentorial white matter and diffusion restriction in the dorsal tegmental tracts ($n=4$) and posterior limb of the internal capsule ($n=1$). Two children had already small defects in the basal ganglia, four had large cysts, adjacent to the anterior horns or body of the lateral ventricles, in some of them with evidence of an earlier bleeding, three had increased pericerebellar CSF spaces. One neonate had two small areas of diffusion-restriction bilaterally in the parietooccipital cortex with subsequent (1 month later) development of cortical defects.

In six children, imaging had been performed in the chronic phase of the disease, between age 3.5 months and 5 years. (Figure 3g-q). Supratentorial atrophy was prominent in four individuals and already present at age 3.5 months. The brain stem was hypotrophic in three patients. Pericerebellar spaces

Fig. 2 Patients with *FBXL4* deficiency share typical facial characteristics. The typical facial features in patients with *FBXL4* deficiency encompass a prominent forehead; thick diffuse eyebrows (synophris in patient 2 and 10); short palpebral fissures (upslanting in patients 7 and 10; broad nasal root and bridge, wide nasal base; and large, low set protruding ears. The philtrum is smooth in patients 7 and 10, who also show thin vermilion of the upper lip



were prominent in five children. The white matter signal was diffusely elevated on the T2-weighted images with restricted diffusion in some patients. Myelination was severely delayed also on the T1-weighted images. Basal ganglia lesions were present in three cases.

In three children, imaging showed acute changes (Fig. 3x-ca). In two, basal ganglia and mesencephalon were swollen and their T2-signal of the basal ganglia was inhomogenously elevated with restricted diffusion. Signal abnormalities and diffusion restriction of the dorsal tegmental tracts were more prominent than in the chronic phase. One child had in addition increased T2 signal and impaired diffusion in both medial thalami and the cervical central spinal cord (not shown). In one child, the oldest of this series, at the age of 11 years there was evidence of an old stroke-like episode involving the right parietal and occipital lobes with cortical haemorrhagic necrosis and a new lesion with impaired diffusion of the left parietooccipital cortex. Clinically she presented with left-sided spastic hemiparesis. This child also had old defects in the basal ganglia and a partly destructed cerebellum.

Biochemical findings

Blood lactate was elevated in every reported case (mean 13.2; median 13.1; range 6.3 – 21; reference range 0.5 - 2.2 mmol/L) (Thomas 2007). Blood alanine concentrations ($n=13$) exceeded the reference range in eight cases (mean 678, median 640; range 353–1580; reference range 120–600 $\mu\text{mol/L}$)

(Blau et al 2003). Blood glucose concentrations were usually normal though hyperglycemia was recorded in one patient and hypoglycaemia in another two patients. Cerebrospinal fluid (CSF) glucose was normal ($n=2$) but lactate was elevated ($n=4$) in those children who had a lumbar puncture performed. Creatine kinase was elevated in four of 11 individuals at initial diagnostic work-up (mean 574, median 184, range 61 – 2000; reference range 25 – 172 U/l [females] and 27 – 242 U/l [males]) (Thomas 2007) and subsequently noted as abnormal (730 and 2263 U/L) in a further two patients. Blood ammonia testing was mildly elevated in seven of 13 patients at initial work-up (mean and median 99, range 36–166; reference range 15–70 $\mu\text{mol/L}$) (Thomas 2007). Lysine was elevated in two of nine patients (457 and 628 $\mu\text{mol/L}$; reference range 66–270 $\mu\text{mol/L}$) (Blau et al 2003). When performed, blood urea nitrogen, creatinine, uric acid, amylase and lipase were all reported normal, liver transaminases were generally normal or at maximum very mildly elevated. The interpretation of molecular and mitochondrial respiratory chain specific biochemical data is shown in Supplementary Table 2. All available measurements showed diminished citrate synthase (CS), respiratory chain complexes and mtDNA content. In contrast to patients with typical mtDNA depletion syndromes due to a disorder of mtDNA replication or nucleoside salvage/synthesis, the mtDNA / CS ratio was normal in patients with *FBXL4* deficiency.

Muscle tissues (available from one patient included in this study) revealed reduced activity in COX-staining indicating a generally reduced number of mitochondria. However,




Fig. 3 Magnetic resonance imaging of the brain from patient 2 (4 days), patient 4 (9 months) and patient 19 (3 years). Patient 2 (age 4 days). Axial T2-weighted images (a–d) show swollen and slightly hyperintense aspect of supratentorial white matter. There are several defects in the basal ganglia (b). There are two small areas at the parietooccipital border on both sides where the cortex is less well defined (c) with corresponding impaired diffusion (e) and decreased apparent diffusion coefficient (adc) (f). Signal of the dorsal tegmental tracts and hilus of the dentate nucleus is increased (d). In the supratentorial white matter, diffusivity is increased (e) with elevated ADC (f), with exception of the posterior limb of the internal capsule. Patient 4 (age 9 months). Axial T2-weighted images (g–l) demonstrate global supratentorial atrophy, a cavum vergae and a left paraventricular cyst (h) and a mild diffuse increase of the supratentorial

white matter signal (g–i). The tectum (j), pyramidal tracts, dorsal tegmentum (k) and middle cerebellar peduncles (k, l) have an elevated signal. Diffusion is impaired with decreased ADC in the supratentorial white matter (m, n) and the middle cerebellar peduncles, dorsal tegmental tracts and pyramidal tracts (o, p). The sagittal T2-weighted image (q) shows normal volume of the cerebellum. Patient 19 aged 3 years (r–w) and 2.5 months later (x–ca). Severe supratentorial atrophy is evident on the axial T2-weighted images (r–t), with now also thinning of the brain stem (t). White matter signal is diffusely elevated (r–t) with impaired diffusion (u, w) and a corresponding low ADC (v), and 2.5 months later, basal ganglia (y), substantia nigra and red nucleus (z) are grossly swollen and hyperintense with corresponding impaired diffusion (ba) and adc (ca). Also the dorsal tegmental tracts are swollen (aa)

intramitochondrial signals showed a normal pattern. Our findings are in line with the observation by Bonnen that mild

subsarcolemmal accumulations were detected by modified Gomori Trichrome staining of muscle tissue (Bonnen et al

2013) in the absence of ragged red fibers (Gai et al 2013). Furthermore, immunohistochemical staining revealed a decreased number of positively staining mitochondria for all oxidative phosphorylation enzymes and porin (Supplementary Fig. 4). There was a decrease in the number of positive granules but the intensity was unaffected, which is comparable to COX activity staining.

Molecular genetic analyses

Figure 4 summarises all pathogenic mutations identified in *FBXL4* to date (including mutations reported by Bonnen et al 2013; Gai et al 2013 depicted in grey). At present, 28 patients known to carry 23 distinct disease-associated *FBXL4* mutations have been identified. The seven predicted loss-of-function mutations (five nonsense mutations, one frameshift, one 18 bp deletion) and two predicted splice site mutations (affecting exons 4 and 9) are equally distributed over all coding exons. In contrast, 13 of the 14 missense mutations, all affecting evolutionarily-conserved amino acids, ten cluster inside the leucine-rich repeat domains and three around a predicted phosphorylation site at position p.202 (p.Ile205Thr, Asp221Val, Asp221His). The clustering of mutations hints towards an interference of the mutations with the function of *FBXL4* by impairing protein-protein interactions or regulation of *FBXL4*. We found no significant phenotypic differences between patients with biallelic missense or predicted loss of function mutations and as such no obvious genotype-phenotype correlation could be delineated.

Discussion

We describe and review the clinical course in a cohort of 21 patients with biallelic *FBXL4* mutations highlighting the severity of this recently described pan-ethnic mitochondrial disease. Our study has several limitations. This cohort represents the first group of patients with the diagnosis of an *FBXL4*-associated mitochondrial disease and late-onset, milder and atypical presentations of the disease will probably be described in the future, as it becomes routine to include *FBXL4* mutations in the standard diagnostic workup of mitochondrial disease. The retrospective design and the variable follow-up strategies applied resulted in heterogeneous and partially incomplete data regarding biochemical parameters and clinical investigations. Furthermore, both the selection of physicians from the referrers of diagnostic material to specialized laboratories or specialist networks and physicians' reports and assessments as data source carry a high risk of bias. Proxy-reported data may not or only in part reflect patients' and caregivers' perspectives.

In the reported cohort, seven of 21 patients died and survivors are severely handicapped. Most patients were young at follow-up and their symptoms may thus not represent the

complete clinical spectrum of the disease. In the oldest patient, a female, aged 11 years and 7 months at last follow-up, stroke-like episodes and neutropenia evolved as additional clinical features. In 11 of 19 families, parental consanguinity (mostly first-cousin marriages) was reported. The cohort had a preponderance of males (13), but given the small size of the group and the manner in which individuals were recruited for investigation, we believe there may be significant bias.

Based on the observed pattern of clinical features in this cohort, we suggest that mutations in the *FBXL4* gene are considered when children exhibit very early (neonatal in some cases) onset of lactic acidosis, profound muscular hypotonia, failure to thrive often (67 %) associated with characteristic facial features.

While multiorgan involvement is a common finding in mitochondrial disease, the presence of a distinct dysmorphic phenotype is rare (Skladal et al 2003; Thorburn 2004; DiMauro and Gurgel-Giannetti 2005; Böhm et al 2006; Debray et al 2007; Cizkova et al 2008; Chinnery 2010; Emmanuele et al 2012; Desguerre et al 2014; Mayr 2014).

Many patients are critically ill from first presentation and may die at a very young age. In survivors, the initial pattern persists and development, motor and cognitive abilities become most severely impaired when patients grow older. Cardiac involvement in the form of non-progressive cardiomyopathy may be evident at initial presentation or evolve through the course of the disease. Other organs are rarely affected. The clinical course is generally progressive or at best stable and quality of life for patients and caregivers is considerably impaired.

There are no specific routine or basic laboratory parameters other than lactic acidosis and, in some cases, elevated creatine kinase, which may facilitate diagnosis. Where tested, skeletal muscle biochemical analysis reveals a severe, combined respiratory chain defect. Thus, loss of *FBXL4* function results in a severe deficiency of mitochondrial energy metabolism, but rather unusually, this is characterised by a loss of mitochondrial number within cells. Diagnostic workup reveals a generally decreased amount of enzymes of the mitochondrial energy metabolism and mtDNA; the mtDNA/CS ratio remains normal (Supplementary Table 2) (Bonnen et al 2013; Gai et al 2013).

FBXL marks proteins containing an F-box and leucine-rich repeats. Both domains mediate protein-protein interactions. F-box proteins were first characterised as components of SCF ubiquitin-ligase complexes (named after their main components, Skp I, Cullin and an F-box protein), in which they bind substrates for ubiquitin-mediated proteolysis (Kipreos and Pagano 2000). Van Rechem et al (2011) identified *FBXL4* in a screen for proteins interacting with the histone lysine demethylase JMJD2A. These experiments suggest that a SCF ubiquitin ligase complex, that contains cullin 1 and *FBXL4*, coordinates the turnover of JMJD2A and thereby

and the mechanism by which *FBXL4* mutations exert their effect is still unclear and warrants further work. The pattern of missense mutations in domains of protein-protein interaction and no obvious differences between these, as well as predicted biallelic loss of function mutations support an important scaffold function of *FBXL4*.

Brain imaging shows non-specific findings with increased water content of the white matter and rather large but non-specific germinolytic periventricular cysts in neonates. Severe atrophy ensues quickly, and decreased apparent diffusion coefficient (ADC) in the affected white matter suggests intramyelinic oedema. In some patients, central grey matter structures including the mesencephalon show increased volume and T2 signal and decreased ADC, as in other mitochondrial disorders, indicating acute energy failure.

In conclusion, the clinical pattern of early-onset encephalopathy, congenital muscular hypotonia, persistent lactic acidosis associated with the typical facial dysmorphism should prompt direct initiation of molecular genetic analysis, which seems the clearest way to diagnosis. Even though treatment approaches with coenzyme Q₁₀, carnitine and other “mitochondrial medications” did not prove effective, establishment of the diagnosis of *FBXL4* deficiency permits accurate genetic counselling and discussion of future reproductive options, prevents patients undergoing further unhelpful but burdensome diagnostic procedures and allows for accurate prognosis with appropriate end of life planning.

Acknowledgments We gratefully acknowledge the contribution of Georg F. Hoffmann, Franz A. Zimmermann and Richard J. Rodenburg. We thank C. Terrile for technical support.

This project was supported by grants from the BMBF funded German Network for Mitochondrial Disorders (mitoNET #01GM1113C) and by the E-Rare project GENOMIT (01GM1207) and GENOMIT FWF I 920-B13 to WS and 01GM1207 to HP.

RWT and RM are supported by The Wellcome Trust Centre for Mitochondrial Research (906919 Z/11/Z), the Lily Foundation and the UK NHS Highly Specialised Commissioners which funds the “Rare Mitochondrial Disorders of Adults and Children” Diagnostic Service in Newcastle upon Tyne (<http://www.mitoresearch.org.uk/>).

D.E.-F. acknowledges support from the Graduate Academy of the University of Heidelberg, the Young Investigator Award Program at Ruprecht-Karls-University Heidelberg Faculty of Medicine, the Daimler and Benz Foundation (Daimler und Benz Stiftung, Ladenburg, Germany) and the Reinhard-Frank Foundation (Reinhard-Frank-Stiftung, Hamburg, Germany).

Compliance with ethics guidelines

Conflict of interest None.

Human and animal rights and informed consent All procedures followed were in accordance with the ethical standards of the responsible local committees on human experimentation (institutional and national) and with the Helsinki Declaration of 1975, as revised in 2000. Informed consent was obtained by the reporting physicians from their patients for being included in the study.

References

- Acham-Roschitz B, Plecko B, Lindbichler F, Bittner R, Mache CJ, Sperl W, Mayr JA (2009) A novel mutation of the RRM2B gene in an infant with early fatal encephalomyopathy, central hypomyelination, and tubulopathy. *Mol Genet Metab* 98:300–304
- Barbier A, Boivin A, Yoon W et al (2013) New reference curves for head circumference at birth, by gestational age. New reference curves for head circumference at birth, by gestational age. *Pediatrics* 131:1158–1167
- Berger A, Mayr JA, Meierhofer D et al (2003) Severe depletion of mitochondrial DNA in spinal muscular atrophy. *Acta Neuropathol* 105:245–251
- Blau N, Duran M, Blaskovic ME, Gibson KM (eds) (2003) *Physician’s guide to the laboratory diagnosis of metabolic diseases*, 2nd edn. Springer, Berlin
- Böhm M, Pronicka E, Karcmarewicz E et al (2006) Retrospective, multicentric study of 180 children with cytochrome c oxidase deficiency. *Pediatr Res* 59:21–26
- Bonnen PE, Yarham JW, Besse A et al (2013) Mutations in *FBXL4* cause mitochondrial encephalopathy and a disorder of mitochondrial DNA maintenance. *Am J Hum Genet* 93:471–481
- Cenciarelli C, Chiaur DS, Guardavaccaro D, Parks W, Vidal M, Pagano M (1999) Identification of a family of human F-box proteins. *Curr Biol* 9:1177–1179
- Chinnery PF (2010) Defining neurogenetic phenotypes (or how to compare needles in haystacks). *Brain* 133:649–654
- Cizkova A, Stranecky V, Mayr JA et al (2008) *TMEM70* mutations cause isolated ATP synthase deficiency and neonatal mitochondrial encephalomyopathy. *Nat Genet* 40:1288–1290
- Debray FG, Lambert M, Chevalier I et al (2007) Long-term outcome and clinical spectrum of 73 pediatric patients with mitochondrial diseases. *Pediatrics* 119:722–733
- Desguerre I, Hully M, Rio M, Nabbout R (2014) Mitochondrial disorders and epilepsy. *Revue neurologique* 170:375–380
- DiMauro S, Gurgel-Giannetti J (2005) The expanding phenotype of mitochondrial myopathy. *Curr Opin Neurol* 18:538–542
- Emmanuele V, Lopez LC, Berardo A et al (2012) Heterogeneity of coenzyme Q10 deficiency. *Arch Neurol* 69:978–983
- Feichtinger RG, Zimmermann F, Mayr JA, Neureiter D, Hauser-Kronberger C, Schilling FH, Jones N, Sperl W, Kofler B (2010) Low aerobic mitochondrial energy metabolism in poorly- or undifferentiated neuroblastoma. *BMC Cancer* 19:149
- Feichtinger RG, Weis S, Mayr JA, Zimmermann F, Geilberger R, Sperl W, Kofler B (2014) Alterations of oxidative phosphorylation complexes in astrocytomas. *Glia* 62:514–525
- Gai X, Ghezzi D, Johnson MA et al (2013) Mutations in *FBXL4*, encoding a mitochondrial protein, cause early-onset mitochondrial encephalomyopathy. *Am J Hum Genet* 93:482–495
- Haack TB, Gorza M, Danhauser K et al (2014) Phenotypic spectrum of eleven patients and five novel MTFMT mutations identified by exome sequencing and candidate gene screening. *Mol Genet Metab* 111:342–352
- Kipreos ET, Pagano M (2000) The F-box protein family. *Genome Biol* 1: reviews3002.1–reviews3002.7
- Kirby DM, Thorburn DR, Turnbull DM, Taylor RW (2007) Biochemical assays of respiratory chain complex activity. *Methods Cell Biol* 80:93–119
- Mayr JA (2014) Lipid metabolism in mitochondrial membranes. *J Inherit Metab Dis* 38:137–144. doi:10.1007/s10545-014-9748-x
- Meierhofer D, Mayr JA, Foetschl U et al (2004) Decrease of mitochondrial DNA content and energy metabolism in renal cell carcinoma. *Carcinogenesis* 25:1005–1010

- Schwarz JM, Rödelsperger C, Schuelke M, Seelow D (2010) Mutation taster evaluates disease-causing potential of sequence alterations. *Nat Methods* 7:575–576
- Skladal D, Sudmeier C, Konstantopoulou V et al (2003) The clinical spectrum of mitochondrial disease in 75 pediatric patients. *Clin Pediatr* 42:703–710
- Thomas L (2007) *Labor und Diagnose*, 7th ed., Stuttgart:Thieme
- Thorburn DR (2004) Mitochondrial disorders: prevalence, myths and advances. *J Inherit Metab Dis* 27:349–362
- Van Rechem C, Black JC, Abbas T et al (2011) The SKP1-Cul1-F-box and leucine-rich repeat protein 4 (SCF-FbxL4) ubiquitin ligase regulates lysine demethylase 4A (KDM4A)/Jumonji domain-containing 2A (JMJD2A) protein. *J Biol Chem* 286:30462–30470
- Winston JT, Koepp DM, Zhu C, Elledge SJ, Harper JW (1999) A family of mammalian F-box proteins. *Curr Biol* 9:1180–1182